BACKGROUND: Catechol-O-methyltransferase (COMT) is the principal enzyme in the conjugation pathway for hydroxylated estrogens. We hypothesize that blood 17b-estradiol (E 2 ) and estrone (E 1 ) levels in postmenopausal women receiving an oral E 2 preparation are dependent on the enzyme activity of COMT. METHODS: To determine the in¯uence of this enzyme on E 2 serum levels three groups of 12 selected from 159 healthy normotensive postmenopausal women were selected according to their codon 158 COMT genotype (COMT HH , COMT HL , COMT LL ) which is known to be associated with enzyme activity. All selected women received one 2 mg tablet estradiol valerate and blood samples were taken before treatment and after 1, 3 and 48 h. RESULTS: After 3 h the serum levels of E 2 were signi®cantly higher in women with the COMT LL genotype (median 69 pg/ml, range 58±91) and the COMT HL genotype (median 69 pg/ml, range 43±84) compared with women with the COMT HH genotype (median 45 pg/ml, range 15±68, P < 0.005). In a univariate analysis of variance, considering age, body weight, and COMT genotype, body weight (P = 0.034) and COMT genotype (P < 0.001) were independently related to the increase of serum E 2 levels, whereas age was not. CONCLUSIONS: Our data demonstrate that serum E 2 levels signi®cantly correlate with the COMT genotype. Differences in COMT genotype might be involved in causing variable effects of estrogens on diseases such as hormone-dependent cancers, coronary heart disease and on ef®cacy of hormone replacement therapy.
Introduction
Catechol-O-methyltransferase (COMT) is involved in catechol homeostasis, which plays both a regulatory and protective role (Ma Ènnisto È and Kaakkola, 1999) . This ubiquitous enzyme catalyses the shift of a methyl group from the co-enzyme Sadenosyl-L-methionine (SAM) to one hydroxyl group of the catechols with Mg 2+ acting as a co-factor (Guldberg and Marsden, 1975) . COMT is furthermore responsible for the regulation of tissue levels of catecholestrogens and catecholamines (Liehr and Roy, 1990; Liehr and Ricci, 1996) . 17b-estradiol (E 2 ) is metabolized by two major pathways, via 16-alpha hydroxylation or via the formation of catechol estrogens (2-hydroxy and 4-hydroxy derivates) (Ball and Knuppen, 1980; Martucci and Fishman, 1993) . Generally, these two catecholestrogens are inactivated by O-methylation, which is catalysed by the COMT enzyme (Yager and Liehr, 1996) . Catecholestrogens can be oxidized to semiquinones and quinones. The 3,4-catecholquinones, which are said to be carcinogenic and originate from the 4-hydroxycatecholestradiol, are able to react with DNA and form depurinated adducts (Cavalieri et al., 1997) . Thus, low COMT activity, resulting in higher concentrations of catecholestrogens, might relate to an increased carcinogenic burden (Lavigne et al., 2001) .
COMT is found in various mammalian tissues, with high levels in the liver, kidney, endometrium and breast, and signi®cant amounts in red blood cells (Weisz, 1994) . A guanine to adenine transition at COMT codon 158 in the membrane bound form (or 108 in the soluble form) resulting in an amino acid change (valine to methionine) has been linked to a 3±4-fold decrease of the methylation activity of the enzyme (Weinshilboum and Raymond, 1977; Boudikova et al., 1990; Dawling et al., 2001) . Homozygous and heterozygous carriage of this polymorphism is found in 25 and 50% of Caucasians respectively (Palmatier et al., 1999) .
To date, there is no data on the effect of the COMT genotype on E 2 serum levels in women, although the molecular mechanism of COMT with respect to the metabolism of estrogen is well described. The aim of the present study was to demonstrate the in¯uence of the COMT genotype on the levels of E 2 and E 1 after the administration of 2 mg E 2 valerate in postmenopausal women. We assume that estrogen serum levels might correlate with COMT activity.
Materials and methods

Subjects
Blood was collected and analysed for the COMT genotype from 159 healthy, normotensive (World Health Organization criteria) Caucasian women, with intact uterus, visiting our outpatient department for menopausal disorders. All women had been amenorrhoeic for at least 6 months, had a FSH >30 IU/ml, and no history of cardiovascular, metabolic, endocrinological or malignant diseases, as assessed in a personal interview. This study was conducted with the approval of our institutional review board, and informed consent was obtained from all participants.
From this pool of 159 women, a total of 36 were selected and divided into three groups of twelve representing the COMT alleles LL, LH and HH. Randomization into the three groups was carried out with a computer generated table of random numbers for each of the three COMT genotypes separately. The examiner was blinded to the COMT genotypes of the women.
All 36 women met the following inclusion criteria: (i) no hormone therapy during the past 12 months; (ii) 17b-estradiol serum levels <50 pg/ml and FSH serum levels >30 mIU/ml; (iii) amenorrhoea (>1 year); (iv) age 45±70 years; (v) good health (normal medical history and physical examination); (vi) no past reproductive endocrine problems (e.g. galactorrhoea) or infertility; (vii) body mass index (BMI) between 20±35 kg/m 2 ; (viii) non smoking; (ix) mammogram indicating no suspicious signs within the last 6 months; (x) no clinically relevant abnormalities in haematological, hepatic (aminotransferase, alkaline phosphatase levels out of the upper limit) or renal functions (serum creatinine levels of >1.5 mg/ml), (xi) glucose metabolism (fasting plasma glucose levels >100 mg/dl), (xii) prolactin (>25 ng/ml) and thyreotropin (TSH) levels (<0.1 ng/ml or >4 ng/ml).
Study design
From all 36 women participating in the study an antecubital venous blood sample was taken using a Vacutainer system (Becton Dickinson, Meylan, France) for the examination of aminotransferase, alkaline phosphatase, creatinine, glucose, TSH, free thyroxine, prolactin, 17b-estradiol, estrone (E 1 ), FSH and LH at 8.00 a.m. after at least 10 h of fasting. After this procedure 2 mg E 2 valerate (Progynova â ) was given orally and blood was collected after 1, 3 and 48 h. At each consecutive blood sampling 17b-estradiol and E 1 were measured. The women had refrained from consuming alcohol 24 h before sampling.
Hormone measurements Serum 17b-estradiol was determined immediately after sampling using an Electro-Chemilumescence-ImmunoAssay (ECLIA) on an Elecsys 2010 immunoassay analyser (Boehringer-Mannheim GmbH, D-682298 Mannheim, Germany). 17b-estradiol levels below the detection limit of this test (<10 pg/ml) were set to zero. Estrone levels were determined using a commercially available radioimmunoassay kit (DSL-8700; Webster, Texas, USA). The assay for 17b-estradiol and E 1 did not show any signi®cant cross-reaction with other substances and had an intra-assay precision of <6.5 and <9.4% respectively. The inter-assay precision were <9 and <11.1% respectively.
Genotyping methodology
Genomic DNA, extracted from anticoagulated blood by the use of a commercially available system (QiAmp Blood Midi Kit; Quiagen, Germany) was analysed for the presence of the G-to-A transition in codon 158 of the COMT gene by a polymerase chain reaction (PCR) based restriction fragment length polymorphism (RFLP) assay. A 237 bp genomic fragment, including the part of exon 4 that contains the polymorphic site, was ampli®ed by PCR using the forward primer TACTGTGGCTACTCAGCTGTGC (positions 1827±1848) (Tenhunen et al., 1994) and the reverse primer GTGAACG-TGGTGTGAACACC [positions 2044±2063, (Tenhunen et al., 1994) ]. Ampli®cation reactions were performed on a Perkin-Elmer GeneAmp PCR System 2400 in a total reaction volume of 50 ml containing 100 ng genomic DNA template, 25 pmol of each primer, 250 mmol/l deoxyribonucleoside triphosphates (dNTPs), 1X SuperTaq Buffer (ViennaLab, Austria) and 0.5 units SuperTaq DNA Polymerase (ViennaLab). The ampli®cation pro®le was as follows: 94°C for 30 s, 56°C for 30 s and 72°C for 30 s, 35 cycles. To simplify the performance and to increase the reproducibility of PCR, PCRmastermixes containing primers, dNTPs and buffer were prepared and used in all ampli®cation reactions. In addition, tubes containing all PCR components and distilled water instead of DNA served as negative controls to check for the presence of DNA that may have been carried over from prior reactions. A total of 5 ml of each PCR product was run on agarose gels to ensure that the expected 237 bp product was generated. The remaining 45 ml was puri®ed by combined ammoniumacetate/ethanol precipitation and digested overnight with 10 IU Nla III (New England Biolabs, MA, USA) at 37°C. The products of the restriction digest were separated on agarose gels (4% SB Fine Gel Agarose; Severn Biotech Ltd., UK) and visualized by SYBR Green I (Molecular Probes Inc., OR, USA). Restriction fragments of 27, 42 and 54 bp were present in every digested sample (Figure 1 ). In the presence of a G at position 1947 (Tenhunen et al., 1994) an additional 114 bp fragment was present, which was cut by Nla III into 96 and 18 bp fragments when position 1947 contained an A (Figure 1) . 
Statistical analysis
Statistical data was evaluated using SPSS 10.0 for windows (SPSS Inc., Chicago, IL, USA). Values are given as the median plus minimum and maximum. Linear correlation analysis (Spearman rank) was used to identify correlations in the parameters tested. The Mann±Whitney U-test and Kruskal±Wallis test was applied for comparisons between the independent groups. Hormone data are shown as box and whisker plots. The upper and lower edges of the box indicate the 25th and 75th percentiles respectively, whereas the median is shown in the box. The whiskers represent minimum and maximum values. We performed a univariate analysis of variance in order to examine whether women's age, body weight, and COMT genotype in¯uence the increase of E 2 after 3 h. The continuous variables used for the univariate analysis showed P-values at a level of >0.53 in the Kolmogorov-Smirnov test, which means that normal distribution can be assumed. All tests were two tailed and a statistical value of P < 0.05 was considered to be signi®cant.
Results
From the 159 women analysed for the COMT genotype, the distribution was as follows: the frequency of the low activity allele (COMT L ) was 194 (61%) and of the high activity (COMT H ) allele 124 (39%). A total of 76 women (48%) were heterozygote (COMT HL ), 24 women (15%) were homozygote for COMT H and 59 women (37%) were homozygote for COMT L .
Of the 36 women for whom consecutive blood E 2 levels were measured, the median age was 56.5 years (range 45±70) and the median BMI 27.8 kg/m 2 (range 21±35). The age, menopause, menarche, partus, abortus, BMI and weight did not differ signi®cantly between the three groups ( Table I ). The pretreatment E 2 levels were associated with BMI and age but not with any COMT genotype. A higher BMI showed signi®cantly higher basal levels of E 1 (r = 0.458, P < 0.01), whereas a higher age was correlated with decreased basal levels of E 2 (r = ±0.535, P < 0.002). The menarche was signi®cantly younger in women with COMT LL when compared with those with COMT HL (P = 0.04) and COMT HH genotypes (P = 0.02) (Figure 2) .
The E 2 levels of the three COMT genotype groups measured before receiving 2 mg estradiol valerate and after 1, 3 and 48 h are shown in Figure 3 . After 3 h the levels of 17b-E 2 were signi®cantly higher in women with the COMT LL (69 pg/ml, range 58±91) and COMT HL (69 pg/ml, range 43±84) genotype (P < 0.005) higher than COMT HH (45 pg/ml, range 15±68 pg/ ml). The pre-treatment, 1 and 48 h E 2 values of the women with different COMT genotypes did not differ signi®cantly. The increase in the E 2 levels in women with COMT LL and COMT HL genotypes were signi®cantly higher with 63 pg/ml (range 42±83, P < 0.001) and 58 pg/ml (range 25±84, P = 0.003) after 3 h than in women with COMT HH (25 pg/ml, range 5±35). The differences in the increase of E 2 after 1 and 3 h were not, however, signi®cant when women with COMT LL and COMT HL genotypes were compared (P = 0.26 and P = 0.54 respectively). The E 1 serum levels of the women with the different COMT genotypes did not differ signi®cantly at any time.
To study the compound effect of COMT and demographic characteristics on the increase of E 2 after 3 h, a univariate analysis of variance was performed. The increase of E 2 levels at 3 h was used as the dependent variable, age, body weight and COMT genotype were used as the independent variables. Body weight (P = 0.034) and COMT genotype (P < 0.001), but not age, were independently related to the increase in E 2 .
Discussion
Fluctuation of serum E 2 is a characteristic feature of the female reproductive cycle. Consequently, blood E 2 levels are controlled by a sensitive feedback mechanism to maintain cycle regularity and reproductive function, controlled by several enzymes involved in the synthesis and degradation of E 2 .
COMT participates in the metabolism of estrogens after their hydroxylation to catecholestrogens by forming O-methylated derivatives. Contrary to these derivates, hydroxylated estrogens can be oxidized to semiquinones and quinones. For example, estrogen-3,4-quinone, which has been shown to bind to DNA, can form depurinating adducts. These adducts may fall off quickly, taking the adenine and guanine bases of the DNA. The gaps formed by this process have a strong potential to create gene mutations and eventually cause cancer (Cavalieri et al., 1997) . Although the formation of 4-OH-estrogens is very low in humans, it is unclear how large a risk this metabolic pathway creates. However, a decreased methylation of hydroxylated estrogens may theoretically increase mutagenic estrogen metabolites.
Mono-O-methylated estrogens have little or no af®nity for estrogen receptors, (Merriam et al., 1980) , thus O-methylation of catecholestrogens is primarily a detoxi®cation pathway. However, 2-methoxy estradiol inhibits the proliferation of several cancer cell lines (Cushman et al., 1995; Klauber et al., 1997) . It is one of the most potent endogenous inhibitors of angiogenesis known (Klauber et al., 1997) .
Our present data demonstrate the in¯uence of the COMT codon 158 polymorphism on E 2 serum levels in postmenopausal women. Serum E 2 levels before treatment were correlated with age, and serum E 1 levels were correlated with the BMI due to the extragonadal conversion of androgens to E 1 . After a single oral dose of estradiol valerate, serum E 2 levels vary signi®cantly, depending on the genotype. After 3 h, E 2 values were higher in the group with at least one low activity allele (COMT LL and COMT HL ) compared with women who were homozygote for the COMT HH genotype.
Another interesting point is the correlation between the COMT LL genotype and the early onset of menarche. This phenomenon could be due to the in¯uence of catecholestrogens on the control of gonadotrophin and prolactin release (Ladosky et al., 1983) . It could also be caused by changes in the metabolism of dopamine and noradrenaline by COMT (Napolitano et al., 1995) since these transmitters stimulate GnRH release and can induce puberty. A microdialysis study, using rats, demonstrated that the release of dopamine is maximal at the age of sexual maturation (Nakano and Mizuno, 1996) . The stimulating or inhibiting effects of catecholamines such as epinephrine and norepinephrine on the hypothalamic±-pituitary±gonadal axis seem to depend on the steroidal milieu (DeMaria et al., 2000) . It has been demonstrated that norepinephrine suppresses GnRH release in ovariectomized rats, whereas it stimulates GnRH and LH secretion in ovariectomized rats treated with estrogen/progestogens. At present, we are trying to verify our observation on the in¯uence of the COMT genotype on the onset of menarche.
The relationship between E 2 levels and the COMT genotype might have an impact on the treatment of postmenopausal women with hormone replacement therapy (HRT). It is a well known fact that the levels of estrogen in the blood during HRT depend on different factors, such as the time of the intake of the tablets and the route of administration, but also on the individual degradation (Tuimala and Vihtama Èki, 1996) . This imbalance and supraphysiological E 2 levels are responsible for bleeding irregularity (Lethaby et al, 2000) , mood changes, and the incidence of hot¯ushes (van de Weijer et al., 1999) . COMT genotype seems to play an independent role in the regulation of estrogen blood levels, which might result in an individual response to HRT with respect to a speci®c allele. Recently, Mitrunen et al. (2002) were able to demonstrate that speci®c COMT genotypes combined with glutathione-S-transferase (GST) genotypes can be used to identify women taking HRT, who are at a high risk of developing breast cancer.
As far as we know this is the ®rst study focusing on the relationship between E 2 levels in postmenopausal women and the COMT codon 158 polymorphism. As signi®cant differences in estrogen levels between women with different COMT alleles could be demonstrated, our data might be of importance for the understanding of inter-individual differences between estrogen levels and hormone dependent cancers, coronary heart disease, and the ef®cacy of HRT.
